Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street’s estimates, boosted in part by the ...

The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

Merck has halted the phase 3 HYPERION trial of ... Winrevair garnered slightly disappointing sales of $149 million in the third quarter of 2024 but a recent survey by Leerink Partners of ...

Merck plans to stop a late-stage study testing ... 2025 Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

The $36 per share, bolt-on deal helps to build Merck's R&D portfolio as it tries to reduce the proportion of sales it makes from $17 billion-plus immuno-oncology blockbuster Keytruda ...

There’s little doubt that losing evobrutinib is a heavy blow, given that Merck had been predicting sales of the drug could top $1 billion per year, despite some concerns that it could cause ...